Skip to main content

Factive Side Effects

Generic name: gemifloxacin

Medically reviewed by Last updated on Aug 23, 2023.

Note: This document contains side effect information about gemifloxacin. Some dosage forms listed on this page may not apply to the brand name Factive.

Applies to gemifloxacin: oral tablet.


Oral route (Tablet)

Fluoroquinolones, including gemifloxacin mesylate, are associated with disabling and potentially irreversible serious adverse reactions that have occurred together, including tendinitis and tendon rupture, peripheral neuropathy, and CNS effects. Discontinue gemifloxacin mesylate and avoid use of fluoroquinolones in patients with these serious adverse reactions. Reserve use of gemifloxacin mesylate for patients with no alternative treatment options for acute bacterial exacerbation of chronic bronchitis. Fluoroquinolones, including gemifloxacin mesylate, may exacerbate muscle weakness in persons with myasthenia gravis. Avoid in patients with known history of myasthenia gravis.

Serious side effects of Factive

Along with its needed effects, gemifloxacin (the active ingredient contained in Factive) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking gemifloxacin:

Less common


Incidence not known

Other side effects of Factive

Some side effects of gemifloxacin may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:


For Healthcare Professionals

Applies to gemifloxacin: oral tablet.


Most side effects reported during postmarketing experience were cutaneous (some were considered serious) and the majority of these were rash. Most rashes occurred in patients younger than 40 years, in women (especially those on hormone replacement therapy), and in patients taking this drug for longer treatment durations (over 7 days).

The phototoxic potential of this drug may be dose-dependent.[Ref]

Common (1% to 10%): Rash

Uncommon (0.1% to 1%): Dermatitis, pruritus, urticaria

Rare (less than 0.1%): Eczema, photosensitivity/phototoxicity reactions

Postmarketing reports: Erythema multiforme, skin exfoliation[Ref]


Common (1% to 10%): Diarrhea, nausea, abdominal pain, vomiting

Uncommon (0.1% to 1%): Constipation, dry mouth, dyspepsia, flatulence, gastritis

Rare (less than 0.1%):Gastroenteritis, nonspecified gastrointestinal disorder

Frequency not reported: Clostridium difficile-associated diarrhea

Postmarketing reports: Antibiotic-associated colitis[Ref]

Nervous system

Cases of sensory or sensorimotor axonal polyneuropathy (affecting small and/or large axons) resulting in paresthesias, hypoesthesias, dysesthesias, and weakness have been reported.[Ref]

Common (1% to 10%): Headache, dizziness

Uncommon (0.1% to 1%): Somnolence, taste perversion

Rare (less than 0.1%): Tremor, vertigo, central nervous system effects

Frequency not reported: Seizures, sensory axonal polyneuropathy, sensorimotor axonal polyneuropathy, paresthesias, hypoesthesias, dysesthesias, neurotoxicity (presenting as encephalopathy)

Postmarketing reports: Exacerbation of myasthenia gravis, peripheral neuropathy (may be irreversible), syncope[Ref]


Common (1% to 10%): Increased ALT, increased AST

Uncommon (0.1% to 1%): Increased GGT, increased total bilirubin

Rare (less than 0.1%): Bilirubinemia[Ref]


Uncommon (0.1% to 1%): Fatigue, fungal infection, increased alkaline phosphatase, increased potassium, decreased albumin, decreased sodium, decreased calcium, decreased total protein, decreased potassium, increased sodium

Rare (less than 0.1%): Asthenia, facial edema, flushing, hot flashes, pain, moniliasis, increased LDH, increased calcium

Frequency not reported: Weakness

Postmarketing reports: Facial swelling, peripheral edema[Ref]


Uncommon (0.1% to 1%): Anorexia, hyperglycemia[Ref]


Uncommon (0.1% to 1%): Increased creatine phosphokinase

Rare (less than 0.1%): Arthralgia, back pain, leg cramps, myalgia

Frequency not reported: Tendinitis

Postmarketing reports: Tendon rupture[Ref]


Uncommon (0.1% to 1%): Increased platelets, decreased neutrophils, increased neutrophils, decreased hematocrit, decreased hemoglobin, decreased platelets, decreased RBCs, increased hematocrit, increased hemoglobin, increased RBCs, leukopenia, thrombocythemia

Rare (less than 0.1%): Anemia, eosinophilia, granulocytopenia, thrombocytopenia

Postmarketing reports: Hemorrhage, increased INR[Ref]


Uncommon (0.1% to 1%): Insomnia

Rare (less than 0.1%): Nervousness


Uncommon (0.1% to 1%): Increased BUN, increased serum creatinine

Rare (less than 0.1%): Increased non-protein nitrogen

Frequency not reported: Acute renal failure

Postmarketing reports: Renal failure[Ref]


Uncommon (0.1% to 1%): Genital moniliasis, genital pruritus, vaginitis

Rare (less than 0.1%): Abnormal urine[Ref]


Rare (less than 0.1%): Abnormal vision

Postmarketing reports: Retinal hemorrhage[Ref]


Rare (less than 0.1%): Dyspnea, pharyngitis, pneumonia

Frequency not reported: Bronchitis[Ref]


QTc interval prolongation has been reported; no cardiovascular morbidity or mortality due to QTc prolongation occurred during studies. Maximum QTc changes occurred 5 to 10 hours after oral administration of this drug. This effect may be dose-related.[Ref]

Frequency not reported: Ventricular extrasystoles

Postmarketing reports: Prolonged QT, supraventricular tachycardia, transient ischemic attack[Ref]


Frequency not reported: Hypersensitivity reactions

Postmarketing reports: Anaphylactic reactions[Ref]


1. Product Information. Factive (gemifloxacin). *GeneSoft Inc. 2003.

2. Lowe MN, Lamb HM. Gemifloxacin. Drugs. 2000;59:1137-47; discussion 1148.

3. Vousden M, Ferguson J, Richards J, Bird N, Allen A. Evaluation of phototoxic potential of gemifloxacin in healthy volunteers compared with ciprofloxacin. Chemotherapy. 1999;45:512-20.

4. Yoo BK, Triller DM, Yong CS, Lodise TP. Gemifloxacin: a new fluoroquinolone approved for treatment of respiratory infections. Ann Pharmacother. 2004;38:1226-35.

5. Bhavnani SM, Andes DR. Gemifloxacin for the treatment of respiratory tract infections: in vitro susceptibility, pharmacokinetics and pharmacodynamics, clinical efficacy, and safety. Pharmacotherapy. 2005;25:717-40.

6. File TM Jr, Mandell LA, Tillotson G, Kostov K, Georgiev O. Gemifloxacin once daily for 5 days versus 7 days for the treatment of community-acquired pneumonia: a randomized, multicentre, double-blind study. J Antimicrob Chemother. 2007.

7. Barrett MJ, Login IS. Gemifloxacin-associated neurotoxicity presenting as encephalopathy. Ann Pharmacother. 2009;43:782-4.

8. Briasoulis A, Agarwal V, Pierce WJ. QT Prolongation and Torsade de Pointes Induced by Fluoroquinolones: Infrequent Side Effects from Commonly Used Medications. Cardiology. 2011;120:103-110.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.